45 assets in Cutaneous Neuroendocrine Carcinoma

Therapeutic assets addressing Cutaneous Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Cutaneous Neuroendocrine Carcinoma	Merck Sharp & Dohme LLC	P3	BB (67)
Cyclophosphamide Cutaneous Neuroendocrine Carcinoma	Merck Sharp & Dohme LLC	P2/3	BB (64)
Atezolizumab Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P2	B (60)
Durvalumab Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P2	B (60)
Fludarabine Cutaneous Neuroendocrine Carcinoma	Sotio Biotech Inc.	P2	B (60)
Ifx-Hu2.0 Cutaneous Neuroendocrine Carcinoma	TuHURA Biosciences, Inc.	P2/3	B (60)
Nivolumab Cutaneous Neuroendocrine Carcinoma	Fred Hutchinson Cancer Center	P2	B (60)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Cutaneous Neuroendocrine Carcinoma	University of Zurich	P2	B (59)
Docetaxel Cutaneous Neuroendocrine Carcinoma	Memgen, Inc.	P2	B (58)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Cutaneous Neuroendocrine Carcinoma	Sensei Biotherapeutics, Inc.	P2	B (58)
Ipilimumab Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Prednisone Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Avelumab Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P2	CCC (53)
L19IL2/L19TNF Cutaneous Neuroendocrine Carcinoma	Philogen S.p.A.	P2	CCC (53)
Pd-L1 T-Hank Cutaneous Neuroendocrine Carcinoma	ImmunityBio, Inc.	P2	CCC (53)
TIL Cutaneous Neuroendocrine Carcinoma	Udai Kammula	P2	CCC (53)
Sargramostim Cutaneous Neuroendocrine Carcinoma	Mayo Clinic	P1/2	CCC (48)
Sirolimus Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
225ac-sso110 Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P1/2	CC (45)
azd6750 Cutaneous Neuroendocrine Carcinoma	AstraZeneca	P1/2	CC (45)
Carboplatin Cutaneous Neuroendocrine Carcinoma	Neonc Technologies, Inc.	P1/2	CC (45)
gpc3-car-t cells Cutaneous Neuroendocrine Carcinoma	Sotio Biotech Inc.	P1/2	CC (45)
Mdna11 Cutaneous Neuroendocrine Carcinoma	Medicenna Therapeutics, Inc.	P1/2	CC (45)
neo212 Cutaneous Neuroendocrine Carcinoma	Neonc Technologies, Inc.	P1/2	CC (45)
Oncolytic Virus Rp1 Cutaneous Neuroendocrine Carcinoma	Replimune, Inc.	P1/2	CC (45)
Regorafenib Cutaneous Neuroendocrine Carcinoma	Neonc Technologies, Inc.	P1/2	CC (45)
Retifanlimab Cutaneous Neuroendocrine Carcinoma	Ariceum Therapeutics GmbH	P1/2	CC (45)
Rilvegostomig Cutaneous Neuroendocrine Carcinoma	AstraZeneca	P1/2	CC (45)
Solnerstotug Cutaneous Neuroendocrine Carcinoma	Sensei Biotherapeutics, Inc.	P1/2	CC (45)
Tarlatamab Cutaneous Neuroendocrine Carcinoma	University of Arizona	P1/2	CC (45)
Vidutolimod Cutaneous Neuroendocrine Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Nogapendekin Alfa Inbakicept Cutaneous Neuroendocrine Carcinoma	ImmunityBio, Inc.	P2	CC (44)
Kup-101A Cutaneous Neuroendocrine Carcinoma	Kupando GmbH	P1	CC (43)
ph-762 Cutaneous Neuroendocrine Carcinoma	Phio Pharmaceuticals Inc.	P1	CC (43)
Tacrolimus Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
vet3-tgi Cutaneous Neuroendocrine Carcinoma	KaliVir Immunotherapeutics	P1	CC (43)
Cdx 1140 Cutaneous Neuroendocrine Carcinoma	University of Southern California	P1	CC (41)
crd3874 Cutaneous Neuroendocrine Carcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
ff-10850 topotecan liposome Cutaneous Neuroendocrine Carcinoma	Fujifilm Pharmaceuticals U.S.A., Inc.	P1	CC (41)
Mem-288 Intratumoral Cutaneous Neuroendocrine Carcinoma	Memgen, Inc.	P1	CC (41)
mq719 Cutaneous Neuroendocrine Carcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Recombinant Flt3 Ligand Cutaneous Neuroendocrine Carcinoma	University of Southern California	P1	CC (41)
Tocilizumab Cutaneous Neuroendocrine Carcinoma	University of Southern California	P1	CC (41)
Anti-Pd-L1 Monoclonal Antibody Ck-301 Cutaneous Neuroendocrine Carcinoma	Checkpoint Therapeutics, Inc.	P1	CC (40)
Bl-M14D1 Cutaneous Neuroendocrine Carcinoma	SystImmune Inc.	P1	NR ()